Clinical Study Details

Title

Aromatase Inhibitor Growth Study

Description

This randomized trial compares the growth promoting effects of letrozole (2.5 mg daily) to anastrozole (1 mg daily) in adolescent males, on the premixe that reduced estrogen levels allows for a longer duration of growth..

Eligibility

To be eligible for this study you must:

Be male
At least 10 years of age
Have a Bone age of 14 years or younger
Be in puberty - LH greater than 0.3 AND Testosterone greater that 15
Height less than the 5th percentile OR PAH more than 10cm BELOW the MEASURED (adjusted) midparental height (Best if BOTH criteria are met)

If your child has any of the following, he CANNOT take part in the study:

Is a female
Primary testicular failure
GH therapy is NOT an exclusion (assure GH consent is ALSO signed
Procedures Blood tests at baseline and every six months (T, DHT, Andro, E1, E2, LH, FSH, IGF-1 IGFBP-3)
Annual Bone Age
DXA every 2 years
Contact

 If you are interested in participating in this study and you meet the inclusion criteria, please contact: Kirk Neely, MD - 650 723- 5791

Please review the consent form for more information

Consent Form

Assent Form - ages 10-17

Study Form